Endoscopic resection of esophageal granular cell tumor

Manuela Canhoto\textsuperscript{a,*}, Sandra Barbeiro\textsuperscript{a}, Filipe Silva\textsuperscript{a}, Bruno Arroja\textsuperscript{a}, Cláudia Gonçalves\textsuperscript{a}, Isabel Cotrim\textsuperscript{a}, Cristina Amado\textsuperscript{b}, Maria Fernanda Cunha\textsuperscript{b}, Helena Vasconcelos\textsuperscript{a}

\textsuperscript{a} Department of Gastroenterology, Centro Hospitalar Leiria-Pombal, EPE, Leiria, Portugal
\textsuperscript{b} Department of Anatomopathology, Centro Hospitalar Leiria-Pombal, EPE, Leiria, Portugal

Received 16 January 2013; accepted 22 March 2013
Available online 15 July 2013

Granular cell tumor (GCT) was first reported by Abrikossoff by the name of granular cell myoblastoma.\textsuperscript{1}
These tumors are found mainly in skin, oral cavity and digestive tract. Most are benign lesions, but there are reports that malignancy may occur in 1–2%.\textsuperscript{2}

The diagnosis is made by histopathology. GCT has eosinophilic cytoplasmatic granules and positivity for S-100 protein and neuron specific enolase. Although their cellular origin remained controversial for years, currently it is thought that GCT originates from Schwann cells.\textsuperscript{2}

A 54-year-old man presented with epigastric pain and was submitted to upper endoscopy. The endoscopy revealed a 10 mm subepithelial esophageal lesion above the esophagogastric junction. The lesion had a yellowish-white appearance, covered with normal mucosa, and was firm when prodded with the biopsy forceps. Although these characteristics are typical of CGT, it is not possible to make an accurate differential diagnosis from other subepithelial lesions such as lipomas by endoscopy.\textsuperscript{3}

Biopsies (bite-on-bite) were performed and histopathological evaluation was suggestive of GCT.

The lesion was characterized by ecoendoscopy as hypoechoic, heterogeneous and limited to the submucosa.

Ultrasonography evaluation was important in the pre-treatment evaluation to confirm that the tumor was limited to the submucosa and presented minimal risk of perforation during resection.\textsuperscript{4}

The patient was being evaluated for an aortic aneurysm and a thoracoabdominal computed tomography was performed with no other lesions.

Due to the most likely benign nature of the lesion, annual follow-up\textsuperscript{3} or endoscopic resection of the lesion were discussed with the patient, who agreed with the endoscopic approach.

The lesion’s borders were marked with Argon-plasma coagulation (Fig. 1), and submucosal injection (10 ml) of sodium chloride 9% solution and adrenaline (1:100 000) elevated the lesion that was completely removed (Fig. 2) with a snare (Endocut\textsuperscript{®} mode 2, ICC200, ERBE Elektromedizin GmbH, Germany). There were no procedure related complications.

The histopathological evaluation confirmed the diagnosis (Fig. 3) and the surgical margin was tumor-free. The tumor site was reviewed six months later, with no lesion.

There are no current guidelines for the treatment of GCT. Two different approaches are possible: endoscopic follow-up for lesions <10 mm or removal of larger lesions (>20 mm), specially when symptomatic or suspicious of malignancy.\textsuperscript{4} Malignant lesions are usually larger than 4 cm, with rapid growth and tend to recur after resection. Endosonography
Endoscopic resection of esophageal granular cell tumor

Figure 1 Upper gastrointestinal endoscopy showed an elevated subepithelial yellowish lesion located just above the esophagogastric junction, coated with normal mucosa. The margins were marked with APC prior to the endoscopic mucosal resection.

Figure 2 Tumor site after endoscopic mucosal resection. The tumor was recovered with a snare.

criteria are present, the tumor is benign, and additional treatment or follow-up is not considered necessary by these authors, but no data exists to determine the cost effective approach in the management of GCT, and the risk/benefit of each approach must be considered case by case, involving the patient in decision making.

Fanburg-Smith and colleagues proposed six histological criteria to determine possible malignancy. If none of these criteria are present, the tumor is benign, and additional treatment or follow-up is not considered necessary by these authors, but no data exists to determine the cost effective approach in the management of GCT, and the risk/benefit of each approach must be considered case by case, involving the patient in decision making.

Figure 3 The resected lesion was a polypoid tumor, with 13 mm, covered with normal malpighian epithelium; (a) below the lamina propria, the stroma was infiltrated by cells with eosinophilic cytoplasm of granular appearance, no atypia or mitotic figures were seen; (b) PAS positivity; (c) CD 68 positivity; (d) diffuse expression of S-100 protein shown by immunohistochemical stain.
Ethical disclosures

Protection of human and animal subjects. The authors declare that no experiments were performed on humans or animals for this study.

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Conflicts of interest

The authors have no conflicts of interest to declare.

References